Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data Analytics & AI · R for trial analysis

The Benefits of R Programming in Clinical Trial Data Analysis

The advantage of R in trial analysis lies neither in its zero licence cost nor in its graphical capabilities. Rather, an analysis written in R can be distributed with its dependencies pinned and re-run by another analyst, which is the only durable remedy for discrepancies between what a trial pre-specified and what it reported. Regulators now accept R-based submissions, but the benefit depends on a discipline that R does not itself enforce.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time12 minutes Sources55 peer-reviewed

The case for R in clinical trials is usually made on the grounds of cost and graphics, but both arguments overlook the central issue. The principal problem R addresses is that a substantial proportion of published trials analyse their data differently from the pre-specified plan, and readers cannot determine from the paper whether the change was justified. The cited study, a review of randomised trials in six general medical journals, identified discrepancies between planned and reported analyses. An analysis environment that can be version-pinned and re-executed is a partial remedy for this problem; an environment that has not been pinned is not.

Learning objectives

  • The current status of R-based regulatory submissions, examined pilot by pilot rather than in general terms
  • The reasons the same nonparametric test can return materially different p-values in R, SAS, SPSS and Stata, and the test most affected
  • The current scope of the trial-specific R package ecosystem, including risk indicators, under-reporting detection and adaptive design simulation
  • Selecting between R functions that appear to fit the same model, and the circumstances in which the choice matters
  • The content a statistical analysis plan requires for an R analysis to be reproducible by a reviewer
  • The assumption checks that are unreported in most trials and are least costly to add in R

Common misconceptions

  • “Using R makes an analysis reproducible.” R makes reproducibility achievable but not automatic. Without a pinned package set, a recorded seed and a stored session state, an R script is as irreproducible as any other, and more fragile, because its dependencies change more rapidly.
  • “Regulators do not accept R.” Regulators do accept R. The R Consortium’s Pilot 3 submission of all-R ADaM datasets and displays went to the FDA through the eCTD gateway on 28 August 2023, was resubmitted on 19 April 2024 after verbal feedback, and received an FDA response letter later that year. By 2026 three R-based submissions had been completed and further pilots were in progress.
  • “Any statistical package gives the same answer to the same question.” Running the same five nonparametric analyses in SPSS, SAS, Stata and R produced inconsistent results, with reported p-values differing by between 0.005 and 0.162; the largest divergence occurred in Pearson’s chi-square test on 2x2 tables. A difference of 0.162 crosses any conventional threshold.
  • “If two functions fit the same model they are interchangeable.” In a simulation of four R functions for clustered trial outcomes, mean squared error did not differ between them, but fixed-effect confidence interval coverage did, with lmer performing better when there were only 10 clusters. The choice of implementation matters most in the smallest trials.
  • “R’s value is that it is free.” Licence cost is the least significant property. The principal value lies in an auditable, re-executable analysis and in access to methods implemented before commercial vendors provide them; for example, in a systematic review of multi-arm multi-stage and platform trial design software, four of the nine solutions of immediate interest were R or Stata packages.

The reproducibility problem addressed by R

The analysis should begin with the defect rather than the tool. In a review of randomised trials published in six general medical journals, a pre-specified analysis was available for 89 of 101 trials, or 88% 24. The cited study identified discrepancies between planned and reported analyses 2. In 15% of trials, reporting was too incomplete to determine whether the conducted analysis matched the plan 7,12,20.

The discrepancies were not random. The analysis model differed in 35% of trials, the analysis population in 31%, the covariate set in 26%, and the handling of missing data in 18%. Each of these is a decision that can shift an estimate, and all four are decisions that a reader cannot audit from a published paper 24. The problem is not primarily fraud or even post hoc data dredging; most of it is drift — a model that failed to converge, a covariate that proved to be collinear, a population definition that proved ambiguous — resolved during analysis and never documented 24.

That framing determines what constitutes a benefit. A language that makes the analysis a stored, executable, version-controlled object with a recorded dependency set addresses drift directly, because each change leaves a trace. A language that is merely capable at statistics does not. R can be the first kind and is routinely used as the second. The Pubrica pages on the statistical analysis plan and statistical review cover the pre-specification side of the same problem.

Where pre-specified and conducted analyses diverged

What differedShare of trials
Analysis model35%
Analysis population31%
Covariate set26%
Handling of missing data18%
Any unexplained discrepancyIdentified (the cited study identified discrepancies between planned and reported analyses)
Pre-specified analysis available89 of 101 trials (88%)
Could not be assessed — reporting too incomplete15%

From a review of randomised trials published in six general medical journals, in which a pre-specified analysis was available for 89 of 101 trials (88%). Categories are not mutually exclusive: a trial could diverge on more than one dimension.

Current status of R-based regulatory submissions

The R Consortium’s R Submissions Working Group has been testing this publicly rather than debating it. Pilot 3 submitted ADaM datasets and the displays derived from them, produced entirely in R, to the FDA through the eCTD gateway on 28 August 2023. It was resubmitted on 19 April 2024 after verbal feedback and received an FDA response letter that year 1,4,5. The submission names three FDA reviewers and thirteen Pilot 3 developers, drawn from ten member pharmaceutical companies — which is notable because it indicates that the exercise did not reflect a single company’s idiosyncratic workflow 5.

By 2026 the working group had completed three R-based FDA submissions and had further pilots in progress, two of them launched in 2026. Pilot 1 submitted four R programs. Pilot 4 submitted a WebAssembly-based application in 2024 and Pilot 5 followed in 2025. Over the same period the FDA expanded the range of R file formats it accepts for submitted packages 1.

The evidence indicates that the pathway exists and has been used, but that it is not yet routine. A sponsor submitting in R today is not doing something unprecedented; it is doing something with a small number of documented precedents, which means that the submission package must be assembled with more explanatory care than a SAS equivalent 1,5,9. Our CDISC SDTM and ADaM work is where that assembly happens, and the clinical study report is where the outputs land.

The R Consortium submission pilots, as of 2026

PilotWhat was submittedStatus
Pilot 1Four R programsCompleted
Pilot 3ADaM datasets and displays, produced entirely in RSubmitted through the eCTD gateway on 28 August 2023; resubmitted 19 April 2024 after verbal feedback; FDA response letter received in 2024
Pilot 4A WebAssembly-based applicationSubmitted in 2024
Pilot 5Further submission in the seriesSubmitted in 2025
Further pilotsIn flightTwo launched in 2026

R Submissions Working Group record. Pilot 3 names three FDA reviewers and thirteen developers drawn from ten member pharmaceutical companies. Three R-based FDA submissions had been completed by 2026, and the FDA had expanded the R file formats it accepts for submitted packages.

Variation in p-values across statistical software

This finding should be considered before software choice is treated as cosmetic. Running the same five nonparametric analyses in SPSS, SAS, Stata and R produced inconsistent results across the four packages. The reported p-values differed by as little as 0.005 and as much as 0.162, with the largest divergence in Pearson’s chi-square test on 2x2 tables 10.

A difference of 0.162 is not a rounding artefact. It is sufficient to move a result from one side of any conventional threshold to the other, on the same data, with the same nominal test. The usual explanations are differences in continuity correction, in exact versus asymptotic computation, in default handling of ties, and in whether a correction is applied silently 10. All of those are defensible choices individually. What is not defensible is reporting “Pearson’s chi-square test” as though the name uniquely determined the computation.

Two consequences follow. First, the analysis plan and the methods section should name the function and the arguments, not only the test: the correction applied, the choice between exact and asymptotic computation, and the tie handling. Second, this is an argument for R rather than against it — the defaults are inspectable and the function call is a literal record of what was computed, which is not true of a menu selection.

Software divergence on identical nonparametric analyses

What was comparedFinding
PackagesFour — SPSS, SAS, Stata and R
TestsFive nonparametric tests, run on the same data
Smallest p-value difference between packages0.005
Largest p-value difference between packages0.162, in Pearson’s chi-square test on 2x2 tables

Cross-package comparison of five nonparametric analyses in SPSS, SAS, Stata and R. The divergence arises from differences in continuity correction, exact versus asymptotic computation and default tie handling — which is why naming the test is not the same as specifying the computation.

Scope of the trial-specific package ecosystem

Three examples supported by published evidence, selected because they cover different parts of the trial lifecycle.

Risk-based quality management. The open-source R package {gsm} maps clinical trial data from several source formats and evaluates 12 key risk indicators, with every release tested and qualified before publication 4. That final clause is the important one for a regulated environment: a package whose qualification state is documented can be referenced in a monitoring plan, which an ad hoc script cannot.

Adverse event under-reporting detection. In cross-company validation by three member companies of the IMPALA collaboration, an open-source R package identified half of all detectable adverse-event under-reporting sites as early as a quarter of the way into the study duration. Detecting half the detectable signal at the 25% mark is operationally useful because it is early enough for the finding to inform action 2,24. It should be read alongside the limits discussed on the clinical risk monitoring page: early detection of half the detectable sites means half were not detected at that point 2.

Adaptive and platform trial design. A systematic review of software for multi-arm multi-stage and platform trial design assessed 289 full-text papers 20. Only 96, or 33%, mentioned the software used, and only 44, or 15%, provided it 7,12. Of the solutions identified, nine were of immediate interest: three standalone programs, four R or Stata packages and two online simulators. The 15% figure is the most significant finding — an adaptive design is defined by its operating characteristics, and operating characteristics that cannot be re-simulated cannot be verified 20.

12key risk indicators evaluated by the {gsm} package
50%of detectable under-reporting sites found by a quarter of the way through
15%of 289 assessed papers provided the trial design software they used

Three published findings on trial-specific R tooling: the 12 key risk indicators in the open-source {gsm} risk-based quality management package; the cross-company IMPALA validation by three member companies, in which an open-source R package identified half of all detectable adverse-event under-reporting sites at 25% of study duration; and the systematic review of multi-arm multi-stage and platform trial design software, in which 96 of 289 full-text papers (33%) mentioned their software and 44 (15%) provided it.

Discrepancies between functions fitting the same model

Cluster randomised and multi-centre trials expose a problem that appears technical but is not. Several R functions will fit a mixed model to clustered outcome data, and they are routinely treated as interchangeable. A simulation study compared four R functions for clustered trial outcomes, with 2,000 repetitions per setting and cluster counts from 10 to 100, and used a worked example with 1,428 participants in 15 clusters 5,12,20,24.

The results were mixed. Mean squared error did not differ between the four functions — so if only the point estimate is of interest, the choice is immaterial 12. Confidence interval coverage for the fixed effect did differ, with lmer performing better when there were only 10 clusters. That is precisely the range most real cluster randomised trials occupy: a few dozen clusters at most, often fewer than 20. The implementation choice is therefore irrelevant in the large-cluster case, which is rare, and material in the small-cluster case, which is common.

The practical rule is that, with few clusters, the analysis plan should state the function and the inference method and justify the choice against the expected number of clusters rather than the desired number. If the coverage behaviour of the chosen approach at the expected cluster count is unknown, it should be simulated — which in R requires a short script rather than a project. The Pubrica biostatistics team does this as a matter of routine for cluster designs.

Under-reporting of assumption checks

A scoping review of randomised trials with ordinal outcomes in four major journals identified 309 records and included 144 eligible studies 7. The target parameter was an odds ratio in 78 studies, or 54%. The outcome was dichotomised in 47 studies, or 33% 20. A proportional odds model was used in 64 studies, or 44%. And 86 studies, or 60%, did not explicitly check or describe whether their statistical method’s assumptions held.

Taken together, nearly half the studies fitted a proportional odds model, a model whose entire interpretation depends on the proportional odds assumption, and a clear majority of all studies reported no assumption check of any kind 7. Separately, a third discarded the ordering of their outcome by dichotomising it, which entails a loss of power and often a loss of the clinically relevant distinction as well 7.

This is the least costly problem described in this article to remedy, and it is the strongest practical argument for a scripted analysis environment. An assumption check in R is a few lines appended to the model fit; it runs every time the analysis runs, and it leaves a printed record in the output. Assumption checks go unreported rarely because the analyst lacks the knowledge; more often, the check was performed once interactively, was not part of the pipeline, and so never reached the log that became the report.

An auditable analysis workflow

Four components, none of them unusual, all of which an R analysis can include and frequently does not.

A pinned dependency set. Record the R version and the exact version of every package used, in a lockfile stored with the analysis. Without this, re-running the analysis a year later reproduces the behaviour of the packages at that time, not their behaviour at database lock. This is the most common reason an R analysis fails to reproduce, and it is unrelated to statistics.

A recorded seed and a stored session record. Any imputation, bootstrap, permutation test or simulation requires its seed in the script, not entered at the console. The session record — R version, platform, loaded packages and their versions — belongs in the output file, where it remains with the result.

One script per output, driven from a single entry point. This ensures that the chain from analysis dataset to table is traceable without reference to the project history, and that re-running everything requires one command rather than a remembered sequence.

A written statement of the change log. Every deviation from the analysis plan, with the date and the reason, recorded contemporaneously. This is the direct countermeasure to unexplained discrepancies between planned and reported analyses: a discrepancy with a dated reason attached is not an unexplained one 24. Support for this is provided across the Pubrica data management plan, research data service and interpretation and visualisation work.

The software and reproducibility paragraph of a statistical analysis plan (versions and values below are illustrative)

Names a language

All statistical analyses will be performed using R. The primary outcome will be analysed using a mixed effects model accounting for clustering by site, with treatment as a fixed effect. Statistical significance will be assessed at the two-sided 5% level. Analyses will be conducted according to the intention-to-treat principle, and missing data will be handled using multiple imputation.

No version and no lockfile. “Using R” names a language whose package set changes continuously; the analysis cannot be re-executed as run, which is the only reproducibility claim that counts.

No function named. Several R functions fit a mixed model to clustered data, and the simulation evidence shows they differ in fixed-effect coverage at small cluster counts — the regime this trial is in.

No inference method. Degrees of freedom, correction and tie handling are all unstated, and the nonparametric comparison across four packages shows that leaving these to defaults can move a p-value by up to 0.162.

No assumption check pre-specified. Sixty per cent of trials with ordinal outcomes report none; writing none into the plan guarantees it.

No seed and no imputation detail. “Multiple imputation” without a seed, a count or an imputation model is not reproducible even by the analyst who ran it.

Specifies a computation

All analyses will be performed in R version 4.4.1 under a project-level lockfile recording the exact version of every package used; the lockfile and the session record will be archived with the analysis outputs. The primary outcome will be analysed with a linear mixed model fitted by lme4::lmer, with treatment as a fixed effect and a random intercept for site, and inference on the treatment effect based on Satterthwaite degrees of freedom; lmer was chosen over the alternatives because the trial has 15 sites and simulation evidence indicates better fixed-effect confidence interval coverage for this function at small cluster counts. The proportional odds assumption for the secondary ordinal outcome will be checked and the check reported whether or not it is satisfied; if it does not hold, the pre-specified fallback is a partial proportional odds model, specified here rather than chosen later. Missing data will be handled by multiple imputation with 50 imputations using mice, seed 20240117 set in the analysis script, with the imputation model and the variables included in it specified in Appendix C. Any deviation from this plan will be recorded in a dated change log held with the analysis code and reproduced in the clinical study report.

The analysis can be re-executed exactly, because the R version, the package versions and the seed are all recorded artefacts rather than recollections.

The function choice is stated and justified against the actual number of clusters, which is the dimension the simulation evidence says matters.

The assumption check is pre-specified along with what happens if it fails, which removes the most common route from a failed assumption to an unreported model change.

The imputation is specified tightly enough that a reviewer can tell whether the imputation model was compatible with the analysis model.

A dated change log converts any later deviation from an unexplained discrepancy into an explained one.

The reviewer’s question is never “was R used”. It is “if this were re-run, would the same number result”. Only the second version answers it, and the cost of writing it is an afternoon at the planning stage rather than a defence at review.

Limitations of R

Three limitations are stated explicitly, because an account that lists only benefits does not support a decision.

It does not provide a validated environment by default 14,18,55. A commercial package arrives with a vendor’s validation documentation; an R installation arrives with CRAN. The gap is bridgeable — {gsm} is an example of a package with a documented qualification process for every release — but bridging it is work that has to be resourced and assigned to someone, and in a regulated submission it has to be described 4.

It does not provide stability without effort. The same openness that makes new methods available years before a vendor implements them means that the software environment changes. A package that changed a default between versions will silently change the results, which is why the pinned dependency set is not optional hygiene but the core of the workflow.

Nor does it guarantee a correct analysis. None of the evidence above suggests that R-analysed trials are better analysed. The ordinal outcomes review found 60% of studies reporting no assumption check irrespective of software; the pre-specification discrepancies were found across trials using a range of software 7,24. R lowers the cost of doing the right thing and leaves a better trace when it is done. It does not make the choice on the analyst’s behalf.

Key points

Key points

The benefit of R in trial analysis is auditability rather than economy. The defect it addresses is well documented: the cited study of randomised trials across six general medical journals identified discrepancies between planned and reported analyses, with the analysis model differing in 35% of trials and the population in 31%. A scripted, version-pinned analysis ensures that any deviation leaves a trace. Regulatory acceptance is established but supported by few precedents: the R Consortium’s Pilot 3 all-R ADaM submission reached the FDA through the eCTD gateway on 28 August 2023 and received a response letter after resubmission in April 2024, with three R-based submissions completed by 2026. Two cautions apply irrespective of language. Identical nonparametric tests returned p-values differing by up to 0.162 across SPSS, SAS, Stata and R, so the analysis plan should name the function and its arguments rather than the test. In trials with ordinal outcomes, 60% reported no assumption check, an omission that a scripted pipeline remedies at the cost of a few lines of code.

Application to your study

Application to your study

  1. Pin dependencies at the outset. Record the R version and every package version in a project lockfile, and archive it with the outputs. Without this record, an analysis cannot be re-run as originally conducted.
  2. Specify functions rather than tests in the analysis plan. Rather than “chi-square test”, specify the function, the correction and the choice between exact and asymptotic methods; the cross-package comparison showed p-values diverging by up to 0.162 on identical data.
  3. Justify the implementation with reference to the number of clusters. With fewer than approximately 20 clusters, state which function is used for the mixed model and why, and simulate its coverage if this is not already known.
  4. Pre-specify the assumption check and the alternative analysis. Record what will be checked, that the check will be reported regardless of its result, and which model will be fitted if the assumption fails.
  5. Set every random seed within the script. Imputation, bootstrap, permutation and simulation all require a seed written in the code rather than entered at the console.
  6. Maintain a dated deviation log from the date the plan is signed. Every change should be recorded with its date and reason and carried into the clinical study report. This converts an unexplained discrepancy into an explained one.
  7. Document the qualification state of any package you rely on. For a regulated submission, state which packages were used, at which versions, and what evidence of qualification exists for them.

Frequently asked questions

There is a documented pathway. The R Consortium’s Pilot 3 submitted ADaM datasets and the displays derived from them, produced entirely in R, through the eCTD gateway on 28 August 2023; it was resubmitted on 19 April 2024 after verbal feedback and received an FDA response letter that year. By 2026 the R Submissions Working Group had completed three R-based FDA submissions, with further pilots in progress including two launched in 2026, and the FDA had expanded the range of R file formats it accepts for submitted packages. The practical caveat is that these are precedents rather than routine practice: an R-based submission package benefits from more explanatory material about the environment and package qualification than a conventional one would require.

Not always, and the differences can be material. A comparison of five nonparametric analyses run in SPSS, SAS, Stata and R found inconsistent results across all four packages, with reported p-values differing by between 0.005 and 0.162. The largest divergence was in Pearson’s chi-square test on 2x2 tables. The causes are mundane — whether continuity correction is applied, exact versus asymptotic computation, default tie handling — but a difference of 0.162 is large enough to move a result across any conventional threshold. The implication is not that one package is correct; it is that the test name does not uniquely specify the computation, so the analysis plan must name the function and its arguments.

It depends principally on the number of clusters. A simulation study of four R functions for clustered trial outcomes, with 2,000 repetitions per setting and cluster counts from 10 to 100, found no difference in mean squared error between the functions, but did find differences in fixed-effect confidence interval coverage, with lmer performing better when there were only 10 clusters. With many clusters, therefore, the choice is close to immaterial; with 10 to 20, which is typical of real cluster randomised trials, it affects interval coverage. The function and the inference method should be pre-specified, and the choice justified against the expected cluster count rather than left to a default.

Base R and CRAN do not arrive with vendor validation documentation, so validation is something the sponsor establishes rather than inherits. That is a real cost, not a formality, and it has to be assigned to someone. It is also bridgeable: the open-source {gsm} package for risk-based quality management, which evaluates 12 key risk indicators and maps data from several source formats, is tested and qualified before every release, and a documented qualification process of that kind is what makes a package referenceable in a monitoring plan or an analysis plan. For a submission, describe the environment, the package set with versions, and whatever qualification evidence exists for the packages doing the statistical work.

Drift between what was planned and what was conducted, usually undocumented. In a review of randomised trials published in six general medical journals, a pre-specified analysis was available for 89 of 101 trials. The cited study identified discrepancies between planned and reported analyses, and in 15% of trials reporting was too incomplete to assess. The most common divergences were in the analysis model (35%), the analysis population (31%), the covariate set (26%) and the handling of missing data (18%). Most of this reflects not misconduct but routine problem-solving during analysis that was never documented, which is why a dated deviation log is the direct remedy.

Both, and the trial-specific layer has grown substantially. For risk-based quality management, {gsm} maps trial data from several source formats and evaluates 12 key risk indicators, with every release tested and qualified before publication. For safety signal detection, an open-source package validated across three IMPALA member companies identified half of all detectable adverse-event under-reporting sites by a quarter of the way into study duration. For adaptive designs, a systematic review of multi-arm multi-stage and platform trial design software found nine solutions of immediate interest, four of them R or Stata packages. The same review found that only 15% of 289 assessed papers actually provided the software they used, which is the real constraint on reusing published designs.

They should be pre-specified, run within the pipeline, and reported whether or not the result is favourable. The reporting gap is wide: in a scoping review of 144 randomised trials with ordinal outcomes across four major journals, 86 studies, or 60%, did not explicitly check or describe whether their method’s assumptions held, while 64 studies, or 44%, used a proportional odds model whose interpretation depends on precisely that assumption. A third of the studies dichotomised the outcome instead, which discards information and often the clinically relevant distinction. The defensible approach is to state the model, state the assumption check, and state in advance which model will be fitted if the check fails.

No, and treating it in that way leads to inadequately resourced migrations. Licence cost is the least consequential difference. The benefits that are supported are an analysis that is a stored, re-executable, version-controlled object; access to methods implemented long before commercial vendors provide them; and a function call that is a literal record of what was computed rather than an unrecorded menu selection. Against these, the sponsor assumes responsibility for environment validation, package qualification and the discipline of pinning dependencies, none of which R provides automatically. The decision should be based on reproducibility and method availability, with the validation work costed realistically.

References

  1. R Consortium R Submissions Working Group. R Submissions Working Group: 2026 Plans and 2025 Success. R Consortium. 2026. read 9 October 2026. r-consortium.org
  2. Koneswarakantha B, Adyanthaya R, Emerson J, et al. An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium. Therapeutic Innovation & Regulatory Science. 2024;58:591-599. doi:10.1007/s43441-024-00631-8 read 9 October 2026. doi.org/10.1007/s43441-024-00631-8
  3. de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024;58(3):483-494. doi:10.1007/s43441-024-00613-w read 9 October 2026. doi.org/10.1007/s43441-024-00613-w
  4. Wu G, Childress S, Wang Z, Roumaya M, McLaughlin Stern C, Dickens C, Wildfire J. Good Statistical Monitoring: A Flexible Open-Source Tool to Detect Risks in Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024;58(5):838-844. doi:10.1007/s43441-024-00651-4 read 9 October 2026. doi.org/10.1007/s43441-024-00651-4
  5. Leng N, Laxamana J; R Consortium R Submissions Working Group. News from R Submissions Working Group - Pilot 3 Successfully Reviewed by FDA. R Consortium. 2024. read 9 October 2026. r-consortium.org
  6. Schauberger G, Klug SJ, Berger M. Random forests for the analysis of matched case-control studies. BMC Bioinformatics. 2024;25(1):253. doi:10.1186/s12859-024-05877-5 read 9 October 2026. doi.org/10.1186/s12859-024-05877-5
  7. Selman CJ, Lee KJ, Ferguson KN, Whitehead CL, Manley BJ, Mahar RK, et al. Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review. Trials. 2024;25:241. doi:10.1186/s13063-024-08072-2 read 9 October 2026. doi.org/10.1186/s13063-024-08072-2
  8. Ben AJ, van Dongen JM, El Alili M, et al. Conducting Trial-Based Economic Evaluations Using R: A Tutorial. PharmacoEconomics. 2023;41:1403-1413. doi:10.1007/s40273-023-01301-7 read 9 October 2026. doi.org/10.1007/s40273-023-01301-7
  9. Zhao Y, Xiao N, Anderson K, Zhang Y. Electronic common technical document submission with analysis using R. Clinical Trials. 2023;20(1):89-92. doi:10.1177/17407745221123244 read 9 October 2026. doi.org/10.1177/17407745221123244
  10. Hodges CB, Stone BM, Johnson PK, et al. Researcher degrees of freedom in statistical software contribute to unreliable results: A comparison of nonparametric analyses conducted in SPSS, SAS, Stata, and R. Behavior Research Methods. 2023;55(6):2813-2837. doi:10.3758/s13428-022-01932-2 read 9 October 2026. doi.org/10.3758/s13428-022-01932-2
  11. de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes. Therapeutic Innovation & Regulatory Science. 2022;57(2):295-303. doi:10.1007/s43441-022-00470-5 read 9 October 2026. doi.org/10.1007/s43441-022-00470-5
  12. Wang W, Harhay MO. A comparative study of R functions for clustered data analysis. Trials. 2021;22:959. doi:10.1186/s13063-021-05900-7 read 9 October 2026. doi.org/10.1186/s13063-021-05900-7
  13. Eggleston BS, Ibrahim JG, McNeil B, Catellier D. BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data. Journal of Statistical Software. 2021;100(21):1-51. doi:10.18637/jss.v100.i21 read 9 October 2026. doi.org/10.18637/jss.v100.i21
  14. Bargo PR, Manitz J, Kelkhoff D, Zhang Y, Taylor L, Rickert J, Gotti M, Anderson K, Nicholls A. Developing a Risk-based Approach for Assessing R Package Accuracy. American Statistical Association meeting proceedings (2021). 2021. read 9 October 2026. ww2.amstat.org
  15. Cragg WJ, Hurley C, Yorke-Edwards V, Stenning SP. Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review. Clinical Trials. 2021;18(2):245-259. doi:10.1177/1740774520976561 read 9 October 2026. doi.org/10.1177/1740774520976561
  16. Wan F, Colditz GA, Sutcliffe S. Matched Versus Unmatched Analysis of Matched Case-Control Studies. American Journal of Epidemiology. 2021;190(9):1859-1866. doi:10.1093/aje/kwab056 read 9 October 2026. doi.org/10.1093/aje/kwab056
  17. Koneswarakantha B, Menard T. Open Source Analytics App for Clinical Trials: Letter to the Editor - A Novel App for Insights into Laboratory Data of Clinical Trials. Therapeutic Innovation & Regulatory Science. 2021;55(6):1107-1108. doi:10.1007/s43441-021-00331-7 read 9 October 2026. doi.org/10.1007/s43441-021-00331-7
  18. Gotti M, Krajcik R, Clark A, Kelkhoff D, Zhang Y, Manitz J, Rickert J, Taylor L, Nicholls A, Bargo PR. Paving the Way for Regulatory Submissions Using R: the Risk Assessment Application. American Statistical Association meeting proceedings (2021). 2021. read 9 October 2026. ww2.amstat.org
  19. Brilleman SL, Wolfe R, Moreno-Betancur M, Crowther MJ. Simulating Survival Data Using the simsurv R Package. Journal of Statistical Software. 2021;97(3):1-27. doi:10.18637/jss.v097.i03 read 9 October 2026. doi.org/10.18637/jss.v097.i03
  20. Meyer EL, Mesenbrink P, Mielke T, Parke T, Evans D, Koenig F. Systematic review of available software for multi-arm multi-stage and platform clinical trial design. Trials. 2021;22:183. doi:10.1186/s13063-021-05130-x read 9 October 2026. doi.org/10.1186/s13063-021-05130-x
  21. Kunzmann K, Pilz M, Herrmann C, Rauch G, Kieser M. The adoptr Package: Adaptive Optimal Designs for Clinical Trials in R. Journal of Statistical Software. 2021;98(9):1-21. doi:10.18637/jss.v098.i09 read 9 October 2026. doi.org/10.18637/jss.v098.i09
  22. Diniz MA, Gresham G, Kim S, et al. Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. BMC Medical Research Methodology. 2021;21:244. doi:10.1186/s12874-021-01368-w read 9 October 2026. doi.org/10.1186/s12874-021-01368-w
  23. Kane MJ, Chen N, Kaizer AM, Jiang X, Xia HA, Hobbs BP. Analyzing Basket Trials under Multisource Exchangeability Assumptions. The R Journal. 2020;12(2):359-370. read 9 October 2026. journal.r-project.org
  24. Cro S, Forbes G, Johnson NA, Kahan BC. Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomised trials. BMC Medicine. 2020;18(1):137. doi:10.1186/s12916-020-01590-1 read 9 October 2026. doi.org/10.1186/s12916-020-01590-1
  25. Cameron B, Kane MJ, Esserman D. preference: An R Package for Two-Stage Clinical Trial Design Accounting for Patient Preference. Journal of Statistical Software. 2020;94(2):1-16. doi:10.18637/jss.v094.c02 read 9 October 2026. doi.org/10.18637/jss.v094.c02
  26. Jaki T, Pallmann P, Magirr D. The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials. Journal of Statistical Software. 2019;88(4):1-25. doi:10.18637/jss.v088.i04 read 9 October 2026. doi.org/10.18637/jss.v088.i04
  27. Stroebel A. atable: Create Tables for Clinical Trial Reports. The R Journal. 2019;11(1). read 9 October 2026. journal.r-project.org
  28. Yu H, Li F, Gallis JA, Turner EL. cvcrand: A Package for Covariate-constrained Randomization and the Clustered Permutation Test for Cluster Randomized Trials. The R Journal. 2019;11(2):191-204. read 9 October 2026. journal.r-project.org
  29. Agrafiotis DK, Lobanov VS, Farnum MA, Yang E, Ciervo J, Walega M, et al. Risk-based monitoring of clinical trials: an integrative approach. Clinical Therapeutics. 2018;40(7):1204-1212. read 9 October 2026. journals.sagepub.com
  30. Stenning SP, Cragg WJ, Joffe N, Diaz-Montana C, Choudhury R, Sydes MR, et al. Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study. Clinical Trials. 2018;15:600-609. read 9 October 2026. journals.sagepub.com
  31. von Niederhausern B, Orleth A, Schadelin S, Rawi N, Velkopolszky M, Becherer C, et al. Generating evidence on a risk-based monitoring approach in the academic setting - lessons learned. BMC Medical Research Methodology. 2017;17(1):26. doi:10.1186/s12874-017-0308-6 read 9 October 2026. doi.org/10.1186/s12874-017-0308-6
  32. Brosteanu O, Schwarz G, Houben P, Paulus U, Strenge-Hesse A, Zettelmeyer U, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study. Clinical Trials. 2017;14:584-596. read 9 October 2026. journals.sagepub.com
  33. Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJA, Saad ED. The impact of data errors on the outcome of randomized clinical trials. Clinical Trials. 2017;14(5):499-506. read 9 October 2026. journals.sagepub.com
  34. Hurley C, Shiely F, Power J, Clarke M, Eustace JA, Flanagan E, Kearney PM. Risk based monitoring (RBM) tools for clinical trials: a systematic review. Contemporary Clinical Trials. 2016;51:15-27. read 9 October 2026. journals.sagepub.com
  35. Knepper D, Lindblad AS, Sharma G, Gensler GR, Manukyan Z, Matthews AG, Ahn H. Statistical monitoring in clinical trials: best practices for detecting data anomalies suggestive of fabrication or misconduct. Therapeutic Innovation & Regulatory Science. 2016;50:144-154. read 9 October 2026. journals.sagepub.com
  36. Olsen R, Bihlet AR, Kalakou F, Andersen JR. The impact of clinical trial monitoring approaches on data integrity and cost - a review of current literature. European Journal of Clinical Pharmacology. 2016;72(4):399-412. read 9 October 2026. journals.sagepub.com
  37. Jackson C. flexsurv: A Platform for Parametric Survival Modeling in R. Journal of Statistical Software. 2016;70(8):1-33. doi:10.18637/jss.v070.i08 read 9 October 2026. doi.org/10.18637/jss.v070.i08
  38. Sheetz N, Wilson B, Benedict J, Huffman E, Lawton A, Travers M, et al. Evaluating source data verification as a quality control measure in clinical trials. Therapeutic Innovation & Regulatory Science. 2014;48(6):671-680. read 9 October 2026. journals.sagepub.com
  39. Tudur Smith C, Williamson P, Jones A, Smyth A, Hewer SL, Gamble C. Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit. Trials. 2014;15:1-10. read 9 October 2026. journals.sagepub.com
  40. Macefield RC, Beswick AD, Blazeby JM, Lane JA. A systematic review of on-site monitoring methods for health-care randomised controlled trials. Clinical Trials. 2013;10(1):104-124. read 9 October 2026. journals.sagepub.com
  41. Kirkwood AA, Cox T, Hackshaw A. Application of methods for central statistical monitoring in clinical trials. Clinical Trials. 2013;10(5):783-806. read 9 October 2026. journals.sagepub.com
  42. Bakobaki J, Joffe N, Burdett S, Tierney J, Meredith S, Stenning S. A systematic search for reports of site monitoring technique comparisons in clinical trials. Clinical Trials. 2012;9(6):777-780. read 9 October 2026. journals.sagepub.com
  43. Tudur Smith C, Stocken DD, Dunn J, Cox T, Ghaneh P, Cunningham D, Neoptolemos JP. The value of source data verification in a cancer clinical trial. PLoS ONE. 2012;7(12):e51623. read 9 October 2026. journals.sagepub.com
  44. Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Metro A, Giraudeau B, et al. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies - the Pre-Optimon study. Contemporary Clinical Trials. 2011;32:16-24. read 9 October 2026. journals.sagepub.com
  45. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1):32. doi:10.1186/1745-6215-11-32 read 9 October 2026. doi.org/10.1186/1745-6215-11-32
  46. Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, Pfistner B, et al. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. Clinical Trials. 2009;6(6):585-596. read 9 October 2026. journals.sagepub.com
  47. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD read 9 October 2026. doi.org/10.1136/bmj.39335.541782.AD
  48. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800-804. doi:10.1097/EDE.0b013e3181577654 read 9 October 2026. doi.org/10.1097/EDE.0b013e3181577654
  49. Montori VM, Devereaux PJ, Adhikari NK, Burns KEA, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-2209. read 9 October 2026. school16.sipta.org
  50. King G, Zeng L. Estimating risk and rate levels, ratios and differences in case-control studies. Statistics in Medicine. 2002;21(10):1409-1427. doi:10.1002/sim.1032 read 9 October 2026. doi.org/10.1002/sim.1032
  51. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials. 1997;18:580-593. read 9 October 2026. school16.sipta.org
  52. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Controlled Clinical Trials. 1989;10:209S-221S. read 9 October 2026. school16.sipta.org
  53. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika. 1979;66:403-411. read 9 October 2026. kiwix.lema.org
  54. Miettinen O. Estimability and estimation in case-referent studies. American Journal of Epidemiology. 1976;103(2):226-235. doi:10.1093/oxfordjournals.aje.a112220 read 9 October 2026. doi.org/10.1093/oxfordjournals.aje.a112220
  55. R Validation Hub (Nicholls A, Bargo PR, Sims R). A Risk-based Approach for Assessing R Package Accuracy within a Validated Infrastructure. R Validation Hub (R Consortium working group). read 9 October 2026. pharmar.org

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). The Benefits of R Programming in Clinical Trial Data Analysis. Pubrica. https://pubrica.com/academy/medical-writing/the-benefits-of-r-programming-in-clinical-trial-data-analysis/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Reproducibility block for a statistical analysis plan

This block should be inserted into the analysis plan and completed. Every blank represents a point on which a reviewer may raise questions and which a future analyst needs in order to re-run the work. The deviation log at the end is the element that converts an unexplained discrepancy into an explained one.

R ANALYSIS REPRODUCIBILITY BLOCK

1. ENVIRONMENT
   R version: ______________
   Operating system / platform: ______________
   Dependency management: [ ] project lockfile  [ ] container image
                          [ ] snapshot date  [ ] other: ________
   Lockfile or image reference archived at: ______________________
   Session record written to the output file?  [ ] yes  [ ] no

2. PACKAGES DOING STATISTICAL WORK (list, with versions)
   Package ................ Version ......... Used for ..............
   Package ................ Version ......... Used for ..............
   Package ................ Version ......... Used for ..............
   Qualification evidence available for each?  [ ] yes  [ ] partial
   Notes: ______________________________________________________

3. PRIMARY ANALYSIS - SPECIFIED TO THE FUNCTION CALL
   Model: ______________________________________________________
   Function and package: ______________________________________
   Fixed effects: ______________________________________________
   Random effects / clustering: ________________________________
   Inference method (df, correction, exact vs asymptotic): _____
   Why this function rather than an alternative: _______________
   Number of clusters expected: ______  (if under ~20, justify)

4. ASSUMPTIONS - CHECKED AND PRE-SPECIFIED
   Assumption ............................. How checked ...........
   Assumption ............................. How checked ...........
   Will the check be reported even if satisfied?  [ ] yes
   Pre-specified fallback model if an assumption fails:
   ____________________________________________________________

5. RANDOMNESS
   Seed(s) set in script (not at console): ______________
   Used for: [ ] multiple imputation  [ ] bootstrap
             [ ] permutation test  [ ] simulation  [ ] other
   Number of imputations / replicates: ______

6. MISSING DATA
   Mechanism assumed: ______________________
   Method: ______________________
   Imputation model and variables included: ______________________
   Compatible with the analysis model?  [ ] yes - how checked: ____

7. CODE ORGANISATION
   [ ] One script per output, driven from a single entry point
   [ ] Re-running everything is one command
   [ ] Analysis datasets built by code, not by hand
   [ ] Outputs carry the session record
   Entry point file: ______________________

8. DEVIATION LOG (start when the plan is signed, never backfill)
   Date | What changed | Why | Approved by | Reported in CSR?
   ---- | ------------ | --- | ----------- | ----------------
   .... | ............ | ... | ........... | ................
   .... | ............ | ... | ........... | ................

PRE-SUBMISSION CHECK
  [ ] A colleague re-ran the pipeline from the lockfile and got the
      same numbers
  [ ] Every table in the report traces to a named script
  [ ] Every deviation in the log appears in the report
  [ ] No analysis step exists only in someone's console history

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica writes analysis plans that specify the computation rather than the language (function, arguments, inference method, assumption checks and the alternative analysis if a check fails) and builds the R pipeline so that a reviewer can re-run it from a lockfile and reproduce the reported results. For sponsors transferring an existing programme to R, Pubrica first reproduces the current outputs in the new environment and reports any differences before the transition. Where a submission is involved, Pubrica assembles the environment and package documentation alongside the CDISC datasets.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review an analysis plan and dataset specification and assess whether a reviewer could reproduce the primary result.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.